Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy

Single-Dose, Phase 1b Study to Assess Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in Pediatric Subjects With Mild to Moderate Spasticity Due to Cerebral Palsy

NCT01405950•Acorda Therapeutics

View on ClinicalTrials.gov

Summary

A Single-Dose, Phase 1b, Multicenter, Open-Label Study to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in Pediatric Subjects 2 to 16 Years Old With Mild to Moderate Spasticity Due to Cerebral Palsy.

Detailed Description

Evaluation of the study's progress after the amendment remained challenging with continued pre-screen failures noted in areas of Botox injection inclusion; family participation refusal / disinterest and gastric or jejunostomy tube placement. A third protocol amendment to improve enrollment was discussed with the Investigators who did not believe further amendment would overcome the barriers expressed by parents that would subject their children to an intense study time commitment without direct benefit. The investigative sites were notified that the study was closed to enrollment March 27, 2012.

Eligibility

Age

2 - 16 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have clinically diagnosed spasticity resulting from cerebral palsy
•Have a motor disability resulting from a static, nonprogressive brain injury or malformation occurring prenatally or before the age of 2 years
•Have mild to moderate spasticity at screening
•Have a parent or legally accepted representative able to understand and comply with study requirements who voluntarily provides informed consent and agrees to be primarily responsible for adhering to the requirements of the study

Exclusion Criteria

•Have a history of hypersensitivity or allergic reaction to tizanidine or any of the capsule components
•Have dietary restrictions or food allergies that conflict with a standardized meal
•Have clinically significant psychiatric, gastrointestinal, pulmonary, hematologic, endocrine, cardiovascular, renal, or hepatic disease that requires pharmacologic intervention
•Have an ongoing seizure disorder that requires medical therapy

Locations (1)

University of Louisville Department of Neurology dba Kentucky Neuroscience Research Health Care Outpatient Center (HCOC)

Louisville, Kentucky, United States

Key Dates

Start Date

May 1, 2011

Primary Completion Date

March 1, 2012

Completion Date

March 1, 2012

Last Updated

June 17, 2013

Enrollment

ACTUAL participants

Conditions

Spasticity Due to Cerebral Palsy

Interventions

Zanaflex Capsules

DRUG

Zanaflex Capsules

DRUG

Zanaflex Capsules

DRUG

Zanaflex Capsules

DRUG